Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Table 5 Multivariate regression analysis assessing the effectiveness of tolvaptan
| Variables | HR (95%CI) | P |
| Reduction of urine osmolality over 25% | 20.7 (3.26-132) | < 0.01 |
| Age (yr) | 1.00 (0.93-1.08) | 0.91 |
| HCV antibody positive | 5.93 (1.01-34.8) | 0.05 |
| Uncontrollable liver neoplasms | 0.68 (0.03-1.20) | 0.21 |
| Total bilirubin (per 1.0 mg/dL) | 0.57 (0.35-0.93) | 0.02 |
| Na (per 1.0 mEq/mL) | 0.99 (0.84-1.17) | 0.93 |
- Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685